康龙化成（北京）新药技术股份有限公司 简式权益变动报告书 上市公司名称：康龙化成（北京）新药技术股份有限公司 股票上市地点：深圳证券交易所（A股）、香港联合交易所（H股） 股票简称：康龙化成（A股、H股） 股票代码：300759.SZ/03759.HK 信息披露义务人（一）：深圳市信中康成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区南山街道兴海大道3046号香江金融大厦1314-B8 通讯地址：北京市朝阳区京城大厦16层 信息披露义务人（二）：深圳市信中龙成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区前湾一路1号A栋201室（入驻深圳市前海商务秘 书有限公司） 通讯地址：北京市朝阳区京城大厦16层 签署日期：2025年7月9日 2 1 信息披露义务人声明 一、本报告书依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》 （以下简称"《准则15号》"）及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据 ...

致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年7月7日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...

Core Viewpoint - 康龙化成's management structure has undergone changes, particularly regarding the voting rights and equity ownership among its key executives, which may impact the company's governance and decision-making processes [1][2][3] Group 1: Management Changes - The voting rights agreement established by the company's chairman, CEO, and COO ensures that they act in concert regarding any proposals presented to the board and shareholders [1] - 郑北 has stepped down as a general partner of the employee stockholding platforms, leading to a redistribution of voting rights associated with the A-shares held by these platforms [2] Group 2: Equity Ownership - Following the changes in general partners, the combined equity ownership of 楼柏良, 楼小强, and 郑北 in the company decreased from approximately 19.36% to 18.18% [3]

证券代码：300759 证券简称：康龙化成 公告编号：2025-036 康龙化成（北京）新药技术股份有限公司 | 1. 基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人（一） | Pharmaron Holdings Limited | | | | 住所 | CO Services Cayman Limited, P.O' Box 10008, Willow House, Cricket Square, Grand Cayman, KY1-1001, Cayman lslands | | | | 信息披露义务人（二） 楼小强 | | | | | 住所 | 北京市通州区马驹桥**** | | | | 信息披露义务人（三） | 宁波龙泰康投资管理有限公司 | | | | 住所 | 浙江省宁波杭州湾新区启源路 号 幢 室 39 1 341 | | | | 信息披露义务人（四） 郑北 | | | | | 住所 | 北京市通州区马驹桥**** | | | | 信息披露义务人（五） | 北海多泰创业投资有限公司 | | | | 住所 | 广西壮族自治区北海市银海区湖北路 2 ...

康龙化成（北京）新药技术股份有限公司 关于股东解除一致行动关系的公告 证券代码：300759 证券简称：康龙化成 公告编号：2025-033 本公司股东厦门龙泰鼎盛企业管理合伙企业（有限合伙）、厦门龙泰汇盛企业 管理合伙企业（有限合伙）、厦门龙泰汇信企业管理合伙企业（有限合伙）、厦门龙 泰众盛企业管理合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次解除一致行动关系是因公司股东的普通合伙人暨执行事务合伙人发 生变更所致，不涉及股东持股数量变动； 2、本次一致行动关系解除不会导致公司实际控制人发生变化。 一、基本情况 郑北女士是公司实际控制人之一、董事、执行副总裁，在公司首次公开发行 股票并上市时，其作为员工持股平台的普通合伙人暨执行事务合伙人，实际控制 员工持股平台所持有公司股份的表决权，员工持股平台为郑北女士的一致行动人。 在一致行动关系存续期间，各方在公司重大事项的决策上始终保持一致意见，严 格履行相关承诺事项，不存在滥用自身控制地位的情形。 2025 年 6 月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年5月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 | RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 | RMB | ...

Financial Performance - In 2024, the company achieved a revenue of CNY 12,275.8 million, representing a year-on-year growth of 6.4%[11] - The profit attributable to the owners of the parent company was CNY 1,793.4 million, reflecting a year-on-year increase of 12.0%[11] - The net cash flow from operating activities was CNY 2,576.7 million, a decrease of 6.4% compared to the previous year[11] - Total revenue for the year ended December 31, 2024, was approximately RMB 12,275.8 million, an increase of about RMB 737.8 million or 6.4% compared to 2023[17] - Profit attributable to equity holders of the parent company was approximately RMB 1,793.4 million, representing an increase of about 12.0% from the previous year[17] - Net cash flow from operating activities was approximately RMB 2,576.7 million, a decrease of about 6.4% compared to 2023[17] - The gross profit for 2024 was approximately RMB 4,149.3 million, reflecting a slight increase of 1.3% from 2023[17] - The company achieved operating revenue of 12,275.8 million, a year-on-year increase of 6.4%[36] - The net profit attributable to the parent company was 1,793.4 million, up 12.0% compared to the same period last year[36] Research and Development - The company participated in 781 global innovative drug discovery projects in 2024[12] - The company provided services for 1,066 drug molecules or intermediates, including 782 preclinical projects and 242 clinical I-II phase projects[12] - The company is currently conducting 1,062 clinical trial projects, including 94 phase III clinical trials[12] - In 2024, the company published 42 articles in international academic journals and obtained or submitted 34 domestic and international patents[12] - The company made significant advancements in automation and artificial intelligence technologies, enhancing drug development efficiency[13] - The company continues to strengthen its core competitive advantages in new drug research and development services[13] - The company aims to cultivate more skilled and dynamic talent through various academic platforms and awards to enhance its innovation capabilities[16] - The company is committed to leveraging AI technology for target discovery and drug evaluation, integrating multi-omics data to improve efficiency in drug discovery services[15] - The company is actively exploring AI and machine learning applications in drug discovery and process optimization to enhance R&D efficiency[42][48] - The company has established a comprehensive clinical trial service platform in China and an independent early clinical research center in Maryland, USA, with 96 beds[51] Service Capabilities - The company operates a leading integrated pharmaceutical R&D service platform with 21 R&D centers and production bases across China, the UK, and the US[25] - The laboratory services include drug chemistry, synthesis chemistry, and biological sciences, covering small molecule drugs, oligonucleotides, peptides, and antibody-drug conjugates[28] - The CMC (small molecule CDMO) services support clients in drug development stages, including process development and production for various products[30] - The clinical research services encompass overseas and domestic clinical trials, with a focus on early clinical trials and regulatory submissions[31] - The company has established bioanalytical platforms in China and the US to support global clinical trials for small molecules and biologics[32] - The company aims to enhance its international service capabilities to provide cross-disciplinary and cross-regional solutions for clients[25] - The company is committed to becoming a global leader in multi-therapy drug development services[25] - The company offers large molecule drug discovery and development services, including cell line development and production processes[33] - The company has established a leading integrated pharmaceutical R&D service platform, expanding its capabilities in small molecules, peptides, oligonucleotides, and gene therapy drugs, while maintaining a strong position in drug discovery and early clinical research[83] Environmental and Social Responsibility - The company reduced greenhouse gas emissions by 21% in 2024 compared to 2023, successfully achieving its annual carbon reduction target[40] - The company was included in the S&P Global "Sustainability Yearbook 2025" and improved its MSCI ESG rating to AA[40] Client Engagement and Market Position - The company served over 3,000 global customers in 2024, with revenue from customers using multiple service segments reaching 9,187.8 million, accounting for 74.8% of total revenue[37] - Revenue from the top 20 global pharmaceutical clients was 2,188.5 million, a year-on-year increase of 26.9%, representing 17.8% of total revenue[37] - The company has attracted over 900 new clients in 2024, with nearly 95% of its revenue coming from a loyal and diverse customer base[98] - The company emphasizes strategic partnerships with specific clients, enhancing its technical capabilities and service quality through shared proprietary knowledge and training[99] Governance and Management - The board consists of eight members, including three executive directors, two non-executive directors, and three independent non-executive directors, ensuring diverse governance[133] - The board has reviewed its diversity policy on March 26, 2025, and considers the current implementation effective[175] - The board's structure includes three executive directors, two non-executive directors, and three independent non-executive directors, ensuring a balanced governance approach[171] - The company emphasizes a culture of "employees first, customers at the center," which is integral to its operational strategy[164] - The board will continue to enhance communication with shareholders to improve governance standards and incorporate their reasonable suggestions[168] Financial Strategy and Investments - The company completed the sale of its stake in PROTEOLOGIX, INC. to Johnson & Johnson for approximately USD 102 million, receiving USD 86.195 million after adjustments[74] - The company has committed RMB 280 million as a limited partner in the Yongxin Kangjun Fund, which constitutes a related party transaction under the listing rules[77] - The company has signed a comprehensive strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd., focusing on integrated services for drug discovery, preclinical and clinical development, with an investment totaling RMB 191 million in the AstraZeneca Fund, accounting for 8.46% of the total subscription[76] Risks and Challenges - The company faces risks from fluctuations in the pharmaceutical investment climate and changes in R&D budgets from multinational pharmaceutical companies, which may impact growth expectations[113] - The company has established a strong talent pool but risks losing qualified research personnel to competitors, which could affect service quality[114] - Regulatory compliance is critical, as failure to meet standards could result in operational suspensions or penalties, impacting client relationships[116] - Foreign exchange risks are significant, with a large portion of revenue generated in USD while costs are primarily in RMB, leading to potential volatility[120] Future Outlook - The company aims to enhance its integrated drug R&D service platform, focusing on ADC and peptide services while strengthening its small molecule R&D capabilities[104] - The company plans to expand its customer base in large molecule and cell and gene therapy services, leveraging its existing advantages to improve operational efficiency[104] - The company is committed to a dual-market strategy, enhancing its presence in both domestic and international markets, with a focus on optimizing service platforms and attracting new clients[105] - The company will continue to develop its large molecule and cell gene therapy service platforms, leveraging existing laboratories in the US and UK[108]

Financial Performance - In Q1 2025, the Company reported revenue of RMB 2,671 million, a decrease of 16.0% compared to RMB 3,099 million in Q1 2024 [10] - Net profit for Q1 2025 was RMB 231 million, down 32.5% from RMB 306 million in Q1 2024 [10] - Non-IFRS net profit slightly decreased by 3.1% to RMB 339 million from RMB 349 million in Q1 2024 [10] - Net operating cash flow was RMB 746 million, a decline of 14.4% from RMB 853 million in Q1 2024 [10] Revenue Composition - Revenue from China entities accounted for 88%, while overseas subsidiaries contributed 12% [12] - Laboratory services generated 60% of total revenue, followed by small molecule CDMO services at 22%, and clinical development services at 14% [12] - Revenue from the top 20 pharmaceutical customers grew by 29.1%, while revenue from other customers increased by 14.0% [12] Growth Rates - New purchase orders (POs) achieved over 10% year-on-year growth in Q1 2025 [10] - Revenue from China entities grew by 15.7%, while overseas subsidiaries saw an 18.3% increase [12] - North America revenue increased by 16.8%, and EU revenue grew by 26.6% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024, reflecting a 1.4 percentage point increase [14] - Gross margin for small molecule CDMO services rose to 30.4%, up 2.5 percentage points from 27.9% in Q1 2024 [15] - Clinical development services in China achieved a gross margin of 11.8%, an increase of 2.5 percentage points from 9.3% in Q1 2024 [16] Future Outlook - The Company maintains a revenue growth guidance of 10-15% for 2025 [27] - Despite macroeconomic uncertainties, the Company believes in sustained industry development driven by healthcare demands and technological innovations [27]

Financial Performance - Revenue for Q1 2025 reached RMB 3,099 million, a 16.0% increase from RMB 2,671 million in Q1 2024 [9] - Net profit attributable to shareholders was RMB 306 million, up 32.5% from RMB 231 million in Q1 2024 [9] - Non-IFRS adjusted net profit increased by 3.1% to RMB 349 million from RMB 339 million [9] - Operating cash flow for Q1 2025 was RMB 853 million, a 14.4% increase from RMB 746 million in Q1 2024 [9] Revenue Composition - Revenue from China delivery business grew by 15.7% [11] - Revenue from overseas delivery business increased by 18.3% [11] - Laboratory services contributed 60% to revenue, with clinical research services at 14% and CDMO at 22% [11] - Revenue from top 20 pharmaceutical companies grew by 29.1% [14] Customer Growth - Revenue from North American clients increased by 16.8% [12] - Revenue from European clients rose by 26.6% [12] - Revenue from Chinese clients grew by 13.1% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024 [17] - Gross margin for clinical services increased to 11.8% from 9.3% [19] - Gross margin for large molecule services improved despite being in a construction phase [20] Strategic Outlook - The company aims for a revenue growth target of 10-15% for the full year 2025 [33] - The company emphasizes the importance of health demand and technological innovation in driving industry growth [33]

Core Viewpoint - 康龙化成 has shown strong growth in new orders and continues to enhance its global presence, leading to a positive outlook for the company [1][2]. Financial Performance - In Q1 2025, 康龙化成 achieved revenue of 30.99 billion yuan, a year-on-year increase of 16.03% - The net profit attributable to shareholders was 3.06 billion yuan, up 32.54% year-on-year, while the net profit excluding non-recurring items was 2.92 billion yuan, reflecting a 56.08% increase year-on-year [2]. - The gross margin for Q1 2025 was 66.34%, showing a year-on-year decrease of 1.01 percentage points but a quarter-on-quarter increase of 1.51 percentage points [2]. Business Segments - New orders increased by over 10% year-on-year, with laboratory services and CMC (small molecule CDMO) services both seeing significant growth [3]. - Revenue by segment includes: - Laboratory services: 18.57 billion yuan, up 15.74% year-on-year - CMC (small molecule CDMO) services: 6.93 billion yuan, up 19.05% year-on-year - Clinical research services: 4.47 billion yuan, up 14.25% year-on-year - Large molecule and cell & gene therapy services: 9.87 billion yuan, up 7.94% year-on-year [3]. Investment Outlook - The company is expected to generate revenues of 137.15 billion yuan, 155.39 billion yuan, and 173.88 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.7%, 13.3%, and 11.9% [4]. - The net profit forecasts for the same years are 17.56 billion yuan, 21.77 billion yuan, and 24.71 billion yuan, with corresponding price-to-earnings ratios of 24, 19, and 17 [4].